BackMarksans Pharma Limited Overview

Marksans Pharma Limited Receivables

Marksans Pharma Limited's receivables is $7.6B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$7.57B
↑ 25.58% YoYΔ $1.54B vs prior year quarter

Peer trimmed avg / median

Loading

Marksans Pharma Limited Receivables History

Loading

Marksans Pharma Limited vs. peers: Receivables Comparison

Loading

Marksans Pharma Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Marksans Pharma Limited (MARKSANS.BO) FAQ

The latest receivables for MARKSANS.BO is $7.6B as of September 2026. That compares with $6B in the prior-year period — up 25.6% year over year. Investors often review this figure alongside Marksans Pharma Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, MARKSANS.BO's receivables moved from $6B to $7.6B — a 25.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Marksans Pharma Limited's operating scale or balance-sheet position.

A receivables figure of $7.6B for MARKSANS.BO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MARKSANS.BO's receivables ($7.6B), review year-over-year change from $6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers